Last updated: May 23, 2026
- Polymorph and salt confirmation release specs for tenofovir alafenamide fumarate.
- Residual solvent control and process impurities aligned to reference standards.
- Data package readiness for ANDA/MAA submissions, including stability and impurity profiling.
Which companies supply tenofovir alafenamide fumarate tablets and fixed-dose combinations (FDCs)?
Where formulation capacity concentrates
TAF is most commonly used in:
- TAF + emtricitabine combination tablets (the dominant fixed-dose pair in practice),
- Other combinations depending on region and brand.
As a result, contract manufacturing typically clusters around:
- High-volume tablet compression lines,
- Film coating and packaging capacity,
- Controlled moisture handling steps for tablet stability.
What buyers actually source
Most supply agreements are structured around:
- Finished dosage form (FDF) manufacturing under GMP,
- Packaging services (bottles/blisters, child-resistant packaging where required),
- Stability program management for marketed shelf life.
Key FDF manufacturing considerations for TAF
- Blend uniformity controls driven by low effective dose considerations.
- Tablet hardness/disintegration specs aligned with tolerances that protect dissolution profiles.
- Salt-form stability monitoring through accelerated and long-term studies.
How many TAF suppliers are qualified for global regulatory submissions and DMFs?
Regulatory qualification mechanics
For a supplier to be actionable in launches and filings, it must provide:
- Drug substance DMF coverage (or reference to a holder DMF),
- Batch reproducibility data across multiple campaigns,
- Controlled change management for route or crystallization modifications.
What drives supplier consolidation
TAF’s supply tends to consolidate because:
- Salt-form and crystallization steps are less forgiving than many APIs,
- Impurity control and polymorph risk can require tight in-process controls,
- Compliance histories and inspection outcomes determine qualification speed.
Which suppliers have capacity for tenofovir alafenamide fumarate in high-volume global markets?
Capacity and scaling
High-volume markets require:
- Multi-ton annual capable API production,
- Tablet finishing with redundant lines to avoid supply chain shocks,
- Packaging throughput synchronized with launch schedules.
Common geographic supply patterns
- Asia-based API dominates supply economics for many antiretroviral APIs.
- Global-formulation contractors often support regulated tablet finishing and packaging for multiple brands.
What manufacturing/IP barriers affect supplier entry for tenofovir alafenamide fumarate?
Main barriers
- Process IP and know-how around TAF crystallization and impurity control.
- Polymorph and particle control that affects dissolution and bioequivalence.
- Inspection-readiness and documented GMP system maturity.
Why supplier qualification takes time
Even when a manufacturer can make TAF, qualification requires:
- Comparative impurity profiles vs. reference material,
- Validation of dissolution performance and stability,
- Supply continuity proofs across campaigns.
How to evaluate tenofovir alafenamide fumarate suppliers for quality and supply continuity?
Qualification checklist buyers use
- GMP compliance history for API and finishing sites.
- Audit scope covering change control, deviation handling, OOS/OOT investigation.
- Sterility is not typically relevant for tablets, but microbiological controls and endotoxin are relevant if any non-tablet dosage forms are proposed.
- Stability program coverage aligned to labeled shelf life.
Commercial risk signals
- Single-source reliance for either the fumarate salt-form step or key intermediates.
- Inadequate scale-up traceability from pilot to commercial batches.
- Limited ability to support regulatory filings (DMF completeness, controlled transfer documentation).
Tenofovir alafenamide fumarate supply comparison: API vs. intermediates suppliers
API manufacturers vs intermediates suppliers
- API manufacturers sell the finished fumarate drug substance with salt-form controls.
- Intermediates suppliers reduce upstream risk but still require the API manufacturer to own the salt-form step and final impurity controls.
Which is the binding constraint?
For commercial launch readiness, the binding constraint usually is:
- the final salt-form crystallization and purification step within the drug substance process,
because it anchors impurity profile, particle attributes, and regulatory acceptance.
Key takeaways
- TAF supply is dominated by specialized upstream capability in API salt-form manufacture and high-volume tablet finishing for TAF-based fixed-dose combinations.
- Supplier qualification is constrained by fumarate salt-form control, impurity profiling, and reproducible crystallization across campaigns.
- Buyers should evaluate suppliers on GMP history, DMF/regulatory readiness, stability data availability, and supply continuity planning (including redundancy for key intermediate and salt-form steps).
FAQs
1) What is the difference between supplying tenofovir alafenamide (base) versus tenofovir alafenamide fumarate?
Fumarate supply requires validated salt-form identity and controlled crystallization and purification; specs and impurity profiles differ versus the base form.
2) Can a tablet manufacturer source API from multiple vendors for continuity?
Yes, but it requires regulatory bridging for process changes and bioequivalence alignment, plus validated dissolution and stability for each API lot source.
3) What supplier documents matter most for TAF filings?
A complete DMF (or cross-reference package), impurity specifications, stability summaries, and batch manufacturing records suitable for regulatory review.
4) What are the common quality risks specific to TAF fumarate?
Salt-form variability, particle size distribution drift, and process impurity formation tied to upstream intermediates and crystallization conditions.
5) How do contract manufacturing organizations typically handle TAF packaging and stability?
They run validated packaging lines and manage stability sampling plans under the marketed label configuration (bottles/blisters) to ensure shelf life compliance.
References
- U.S. Food and Drug Administration. Drug Master Files (DMF) regulations and guidance (FDA website).
- ICH. Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.
- ICH. Q3A/Q3B/Q3C impurity guideline suite.
